BACKGROUND: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. METHODS: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. RESULTS AND CONCLUSION: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

Barts Cancer Institute Queen Mary University of London London UK

Cancer Center IRCCS Humanitas Research Hospital Rozzano Milan Italy; Department of Biomedical Sciences Humanitas University Pieve Emanuele Milan Italy

Centre for Haematology Imperial College London Hammersmith Hospital London UK

Clínica Universidad de Navarra CIBERONC Pamplona Spain

Clinical Director Haematology Haemostasis Palliative Care Cellular Pathology Guy's and St Thomas' NHS Foundation Trust London UK

Clinical Hematology Department ICO Hospital Germans Trias i Pujol Josep Carreras Research Institute Universitat Autònoma de Barcelona Badalona Spain

Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece

Department of Hematology and Medical Oncology University Hospital Jena Jena Germany; Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute Jena Germany

Department of Hematology Hemostasis Oncology and Stem Cell Transplantation Hannover Medical School Hanover Germany

Department of Hematology Medical University of Lodz Lodz Poland

Department of Hematology Oncology and Tumorimmunology Campus Virchow Klinikum Berlin Germany; Charité Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin Berlin Germany

Department Of Hematology Portuguese Institute of Oncology Lisbon Portugal

Department of Hematooncology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Medicine 1 Division of Oncology Medical University of Vienna Vienna Austria

Department of Medicine 3 at LMU Hospital Munich Germany

Department of Medicine and Surgery University of Insubria Varese Italy

Department of Radiation Oncology University of Muenster Münster Germany

Department of Stem Cell Transplantation University Hospital Hamburg Eppendorf Hamburg Germany

Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy; Department of Molecular Medicine University of Pavia Pavia Italy

Erasmus MC Cancer Institute Department of Haematology Rotterdam The Netherlands

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy; Department of Pathophysiology and Transplantation University of Milan Milan Italy

Hematology Department Hospital Clínic IDIBAPS Barcelona Spain

Hematology Department Hospital Univesitario y Politecnico La Fe Valencia; CIBERONC IS Carlos 3 Madrid Spain

Hematology Department of Translational and Precision Medicine Sapienza University Rome Italy

Hematology Department University Hospital Hotel Dieu Nantes France

Hematology Division Basel University Hospital Basel Switzerland

Hematology Division University of Milan Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy

Institute of Experimental Cancer Research Department of Internal Medicine 3 University Hospital Ulm Ulm Germany

MDS Unit Hematology DMSC AOUC University of Florence Florence Italy

Munich Clinic Schwabing Academic Teaching Hospital Ludwig Maximilian University Munich Germany

Scientific and Medical Division European Society for Medical Oncology Lugano Switzerland

Service d'Hématologie Oncologie Centre Hospitalier de Versailles Le Chesnay France; UVSQ Inserm CESP Villejuif France

Strategic Research Program on Chronic Lymphocytic Leukemia and Laboratory of B Cell Neoplasia Division of Molecular Oncology Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele Milan Italy

UCLH Centre for Waldenström and Neurohaematology University College London Hospitals NHS Foundation Trust London UK

Université de Paris APHP Hôpital Saint Louis Centre d'Investigations Cliniques Paris France

University Medical Department of Hematology and Immunology France Intergroupe des Leucémies Myéloïdes Chroniques Hôpital Saint Louis Paris France

Zobrazit více v PubMed

Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. PubMed PMC

Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232. PubMed PMC

Lee L.Y., Cazier J.B., Angelis V., et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–1926. PubMed PMC

Passamonti F., Cattaneo C., Arcaini L., et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–e745. PubMed PMC

Garcia-Suarez J., de la Cruz J., Cedillo A., et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13:133. PubMed PMC

Wood W.A., Neuberg D.S., Thompson J.C., et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966–5975. PubMed PMC

Vijenthira A., Gong I.Y., Fox T.A., et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892. PubMed PMC

Chari A., Samur M.K., Martinez-Lopez J., et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3033–3040. PubMed PMC

Mato A.R., Roeker L.E., Lamanna N., et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134–1143. PubMed PMC

Regalado-Artamendi I., Jimenez-Ubieto A., Hernandez-Rivas J.A., et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere. 2021;5:e538. PubMed PMC

Sharma A., Bhatt N.S., St Martin A., et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–e193. PubMed PMC

Passamonti F., Romano A., Salvini M., et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol. 2021;195:371–377. PubMed PMC

Toyoshima Y., Nemoto K., Matsumoto S., et al. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020;65:1075–1082. PubMed PMC

Herzog Tzarfati K., Gutwein O., Apel A., et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021;96:1195–1203. PubMed PMC

Maneikis K., Sablauskas K., Ringeleviciute U., et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583–e592. PubMed PMC

Benda M., Mutschlechner B., Ulmer H., et al. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. Br J Haematol. 2021;195:523–531. PubMed PMC

Greenberger L.M., Saltzman L.A., Senefeld J.W., et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031–1033. PubMed PMC

Herishanu Y., Avivi I., Aharon A., et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–3173. PubMed PMC

Roeker L.E., Knorr D.A., Thompson M.C., et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021;35:2703–2705. PubMed PMC

Perry C., Luttwak E., Balaban R., et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5:3053–3061. PubMed PMC

Ghione P., Gu J.J., Attwood K., et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies. Blood. 2021;138:811–814. PubMed PMC

Lim S.H., Campbell N., Johnson M., et al. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol. 2021;8:e542–e544. PubMed PMC

Gurion R., Rozovski U., Itchaki G., et al. Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2022;107(3):715–720. PubMed PMC

Terpos E., Gavriatopoulou M., Ntanasis-Stathopoulos I., et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11:138. PubMed PMC

Van Oekelen O., Gleason C.R., Agte S., et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39:1028–1030. PubMed PMC

Pimpinelli F., Marchesi F., Piaggio G., et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. 2021;14:81. PubMed PMC

Bird S., Panopoulou A., Shea R.L., et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8:e389–e392. PubMed PMC

Terpos E., Trougakos I.P., Gavriatopoulou M., et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137:3674–3676. PubMed PMC

Pimpinelli F., Marchesi F., Piaggio G., et al. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. J Hematol Oncol. 2021;14:119. PubMed PMC

Harrington P., de Lavallade H., Doores K.J., et al. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 2021;35:3573–3577. PubMed PMC

Harrington P., Doores K.J., Radia D., et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021;194:999–1006. PubMed PMC

Harrington P., Harrison C.N., Dillon R., et al. Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Br J Haematol. 2021;193:692–696. PubMed PMC

Cowling B.J., Ali S.T., Ng T.W.Y., et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020;5:e279–e288. PubMed PMC

Bartoszko J.J., Farooqi M.A.M., Alhazzani W., Loeb M. Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: a systematic review and meta-analysis of randomized trials. Influenza Other Respir Viruses. 2020;14:365–373. PubMed PMC

Cheng V.C., Wong S.C., Chuang V.W., et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2. J Infect. 2020;81:107–114. PubMed PMC

Lewnard J.A., Liu V.X., Jackson M.L., et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ. 2020;369:m1923. PubMed PMC

Matrajt L., Leung T. Evaluating the effectiveness of social distancing interventions to delay or flatten the epidemic curve of coronavirus disease. Emerg Infect Dis. 2020;26:1740–1748. PubMed PMC

Cowling B.J., Zhou Y., Ip D.K., et al. Face masks to prevent transmission of influenza virus: a systematic review. Epidemiol Infect. 2010;138:449–456. PubMed

Leung N.H.L., Chu D.K.W., Shiu E.Y.C., et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med. 2020;26:676–680. PubMed PMC

Cho S.Y., Park S.S., Lee J.Y., et al. Successful prevention and screening strategies for COVID-19: focus on patients with haematologic diseases. Br J Haematol. 2020;190:e33–e37. PubMed PMC

van de Haar J., Hoes L.R., Coles C.E., et al. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020;26:665–671. PubMed

Weisel K.C., Morgner-Miehlke A., Petersen C., et al. Implications of SARS-CoV-2 infection and COVID-19 crisis on clinical cancer care: report of the University Cancer Center Hamburg. Oncol Res Treat. 2020;43:307–313. PubMed PMC

Lemaitre M., Meret T., Rothan-Tondeur M., et al. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J Am Geriatr Soc. 2009;57:1580–1586. PubMed

Baden L.R., El Sahly H.M., Essink B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. PubMed PMC

Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. PubMed PMC

Voysey M., Clemens S.A.C., Madhi S.A., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. PubMed PMC

Meisel R., Kuypers L., Dirksen U., et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2007;109:2322–2326. PubMed

Beck C.R., McKenzie B.C., Hashim A.B., et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza. Other Respir Viruses. 2013;7(suppl 2):72–75. PubMed PMC

Bitterman R., Eliakim-Raz N., Vinograd I., et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018;2:CD008983. PubMed PMC

Winston D.J., Mullane K.M., Cornely O.A., et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:2116–2127. PubMed

Rieger C.T., Liss B., Mellinghoff S., et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) Ann Oncol. 2018;29:1354–1365. PubMed PMC

Mikulska M., Cesaro S., de Lavallade H., et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7) Lancet Infect Dis. 2019;19:e188–e199. PubMed

Cordonnier C., Einarsdottir S., Cesaro S., et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7) Lancet Infect Dis. 2019;19:e200–e212. PubMed

Giesen N., Sprute R., Rüthrich M., et al. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. 2021;147:154–160. PubMed PMC

Wijn D.H., Groeneveld G.H., Vollaard A.M., et al. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer. 2018;104:182–187. PubMed

Bayle A., Khettab M., Lucibello F., et al. Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. Ann Oncol. 2020;31:959–961. PubMed

Muir K.L., Kallam A., Koepsell S.A., Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384:1964–1965. PubMed PMC

Sadoff J., Davis K., Douoguih M. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination - response from the manufacturer. N Engl J Med. 2021;384:1965–1966. PubMed PMC

Bourguignon A., Arnold D.M., Warkentin T.E., et al. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;385:720–728. PubMed PMC

Greinacher A., Thiele T., Warkentin T.E., et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092–2101. PubMed PMC

Larson K.F., Ammirati E., Adler E.D., et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation. 2021;144:506–508. PubMed PMC

Arons M.M., Hatfield K.M., Reddy S.C., et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081–2090. PubMed PMC

Mondi A., Lorenzini P., Castilletti C., et al. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted in an Italian Reference Hospital. Int J Infect Dis. 2021;105:532–539. PubMed PMC

Avanzato V.A., Matson M.J., Seifert S.N., et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183:1901–1912.e9. PubMed PMC

Hao S., Lian J., Lu Y., et al. Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: a case-control study. J Infect Dis. 2020;222:367–371. PubMed PMC

van Kampen JJA, van de Vijver D., Fraaij P.L.A., et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) Nat Commun. 2021;12:267. PubMed PMC

Courtellemont L., Guinard J., Guillaume C., et al. High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection. J Med Virol. 2021;93:3152–3157. PubMed PMC

Peña-Rodrígez M., Viera-Segura O., García-Chagollán M., et al. Performance evaluation of a lateral flow assays for nasopharyngeal antigen detection for SARS-CoV-2 diagnosis. J Clin Lab Anal. 2021;35 PubMed PMC

Pérez-García F., Romanyk J., Gómez-Herruz P., et al. Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection. J Clin Virol. 2021;137:104781. PubMed PMC

Pollock N.R., Jacobs J.R., Tran K., et al. Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts. J Clin Microbiol. 2021;59 e00083-21. PubMed PMC

Thommes L., Burkert F.R., Öttl K.W., et al. Comparative evaluation of four SARS-CoV-2 antigen tests in hospitalized patients. Int J Infect Dis. 2021;105:144–146. PubMed PMC

Merino P., Guinea J., Muñoz-Gallego I., et al. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection. Clin Microbiol Infect. 2021;27:758–761. PubMed PMC

Silva J., Lucas C., Sundaram M., et al. Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. medRxiv. 2021

Wyllie A.L., Fournier J., Casanovas-Massana A., et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020;383:1283–1286. PubMed PMC

Wang W., Xu Y., Gao R., et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–1844. PubMed PMC

Moreira V.M., Mascarenhas P., Machado V., et al. Diagnosis of SARS-Cov-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis. Diagnostics (Basel) 2021;11:363. PubMed PMC

Stanoeva K.R., van der Eijk A.A., Meijer A., et al. Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies. Euro Surveill. 2021;26:2001134. PubMed PMC

Nawar T., Morjaria S., Kaltsas A., et al. Granulocyte-colony stimulating factor in COVID-19: is it stimulating more than just the bone marrow? Am J Hematol. 2020;95:E210–E213. PubMed PMC

Zhang A.W., Morjaria S., Kaltsas A., et al. The effect of neutropenia and filgrastim (G-CSF) in cancer patients with COVID-19 infection. Clin Infect Dis. 2022;74(4):567–574. PubMed PMC

Fajgenbaum D.C., June C.H. Cytokine storm. N Engl J Med. 2020;383:2255–2273. PubMed PMC

Peyvandi F., Artoni A., Novembrino C., et al. Hemostatic alterations in COVID-19. Haematologica. 2021;106:1472–1475. PubMed PMC

Rhee C., Kanjilal S., Baker M., Klompas M. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? Clin Infect Dis. 2021;72:1467–1474. PubMed PMC

Rao S.N., Manissero D., Steele V.R., Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020;9:573–586. PubMed PMC

Aydillo T., Gonzalez-Reiche A.S., Aslam S., et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586–2588. PubMed PMC

Choi B., Choudhary M.C., Regan J., et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291–2293. PubMed PMC

Treon S.P., Castillo J.J., Skarbnik A.P., et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135:1912–1915. PubMed PMC

Dreyling M., Aurer I., Federico M., et al. EHA/ESMO clinical practice gidelines for the management of malignant lymphoma: recommendations for the second phase of the COVID-19 pandemic. Hemasphere. 2021;5:e529. PubMed PMC

Rossi D., Shadman M., Condoluci A., et al. How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 Pandemic. Hemasphere. 2020;4:e432. PubMed PMC

Rajkumar S.V., Dimopoulos M.A., Palumbo A., et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548. PubMed

Terpos E., Engelhardt M., Cook G., et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) Leukemia. 2020;34:2000–2011. PubMed PMC

Terpos E., Kleber M., Engelhardt M., et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254–1266. PubMed PMC

Terpos E., Morgan G., Dimopoulos M.A., et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31:2347–2357. PubMed PMC

Kyriakou C., Molloy S., Vrionis F., et al. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG) Blood Cancer J. 2019;9:27. PubMed PMC

Terpos E., Zamagni E., Lentzsch S., et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22:e119–e130. PubMed

Lakshman A., Rajkumar S.V., Buadi F.K., et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59. PubMed PMC

Rogado J., Gullon P., Obispo B., et al. Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors. Eur J Cancer. 2021;148:58–60. PubMed PMC

Martinez-Lopez J., Mateos M.V., Encinas C., et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:103. PubMed PMC

Group R.C., Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. PubMed PMC

Rajkumar S.V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548–567. PubMed

Rosinol L., Oriol A., Rios R., et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134:1337–1345. PubMed PMC

Attal M., Lauwers-Cances V., Hulin C., et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–1320. PubMed PMC

Dimopoulos M.A., Moreau P., Terpos E., et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309–322. PubMed

Ntanasis-Stathopoulos I., Gavriatopoulou M., Kastritis E., et al. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929. PubMed

Moreau P., Attal M., Hulin C., et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38. PubMed

Yimer H., Melear J., Faber E., et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol. 2019;185:492–502. PubMed PMC

Dimopoulos M.A., Leleu X., Palumbo A., et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–1585. PubMed PMC

Attal M., Richardson P.G., Rajkumar S.V., et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096–2107. PubMed

Dimopoulos M.A., Dytfeld D., Grosicki S., et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–1822. PubMed

Chari A., Vogl D.T., Gavriatopoulou M., et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727–738. PubMed

Lonial S., Lee H.C., Badros A., et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–221. PubMed

Barbui T., Vannucchi A.M., Alvarez-Larran A., et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35:485–493. PubMed PMC

Breccia M., Abruzzese E., Accurso V., et al. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol. 2022;196:559–565. PubMed PMC

Reply to "successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience": A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era